Pfizer Inc. logo

Pfizer Inc. (PFE)

Market Closed
4 Sep, 20:00
NYSE NYSE
$
28. 45
-0.36
-1.2496%
$
159.36B Market Cap
14.55 P/E Ratio
0.68% Div Yield
23.78M Volume
1.43 Eps
$ 28.81
Previous Close
Add Transaction
Day Range
28.38 28.69
Year Range
23.58 29.21
Want to track PFE and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds

Pfizer: Look Beyond COVID-19 And The Patent Cliffs - Robust Long-Term Tailwinds

PFE's bullish support has already been observed at the $25s, with the worst seemingly well behind us. Its core portfolio continues to generate robust growth at +14% YoY in FQ2'24 (excluding Comirnaty and Paxlovid), with Seagen's therapies already at $2.92B in annualized revenues. FY2025 is likely to bring forth an improved YoY comparison as well, with PFE's 3Y cost optimization program expected to boost their gross/ operating margins to pre-pandemic levels.

Seekingalpha | 2 years ago
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know

Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks | 2 years ago
2 Incredibly Cheap Growth Stocks to Buy Now

2 Incredibly Cheap Growth Stocks to Buy Now

Stock market prices don't tell you everything, and that's certainly true with these businesses. Pfizer is paving the way to future growth, but investors might need to be patient.

Fool | 2 years ago
Why Is Pfizer (PFE) Down 5.9% Since Last Earnings Report?

Why Is Pfizer (PFE) Down 5.9% Since Last Earnings Report?

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?

Zacks | 2 years ago
Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs

PFE's digital pharmacy aims to provide patients easy access to its medicines for COVID-19, migraine and other conditions.

Zacks | 2 years ago
Why Walgreens Boots Alliance Plunged Today

Why Walgreens Boots Alliance Plunged Today

Major drugmakers Pfizer and Eli Lilly made major direct-to-consumer announcements. While Walgreens was named as a partner for Pfizer's new direct health platform, it stands to potentially lose out on retail drug sales.

Fool | 2 years ago
Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines

Healthy Returns: What to know about the latest round of Pfizer, Moderna Covid vaccines

A brand new round of Covid shots from Pfizer and Moderna is about to reach Americans. Meanwhile, CNBC tested out Dexcom's new CGM Stelo.

Cnbc | 2 years ago
Pfizer launches new website for migraine, respiratory offerings

Pfizer launches new website for migraine, respiratory offerings

Pfizer Inc is launching a new website to promote and improve access to its health care offerings for migraine and respiratory illnesses.

Reuters | 2 years ago
Pfizer follows Eli Lilly's lead in direct-to-consumer push

Pfizer follows Eli Lilly's lead in direct-to-consumer push

Pfizer Inc. on Tuesday unveiled a new online platform designed to help simplify and coordinate healthcare for consumers, adding momentum to an emerging trend in big pharma that has drawn criticism from some provider groups and policy experts.

Marketwatch | 2 years ago
Is Pfizer Stock Still a Buy After an Unexpected Setback?

Is Pfizer Stock Still a Buy After an Unexpected Setback?

One of Pfizer's vaccine programs failed to demonstrate its utility. Its competitors had the same issue with their programs.

Fool | 2 years ago
FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs

FDA Approves Pfizer & Moderna's Updated COVID-19 Jabs

On Thursday, the FDA cleared new versions of Pfizer's (PFE) and Moderna's (MRNA) COVID-19 vaccines that are designed to match COVID-19 strains currently circulating in the country.

Zacks | 2 years ago
3 Stocks Under $50 Smart Investors Should Buy Hand Over Fist

3 Stocks Under $50 Smart Investors Should Buy Hand Over Fist

It is never too early to start your investment journey.

247wallst | 2 years ago
Loading...
Load More